S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
Log in
TSE:BLU

BELLUS Health Competitors

C$5.07
+0.27 (+5.63 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
C$4.75
Now: C$5.07
C$5.15
50-Day Range
C$4.00
MA: C$4.78
C$5.74
52-Week Range
C$2.70
Now: C$5.07
C$16.68
Volume400,105 shs
Average Volume340,679 shs
Market CapitalizationC$397.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

BELLUS Health (TSE:BLU) Vs. TRIL, CXR, BU, APS, TH, and NEPT

Should you be buying BLU stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to BELLUS Health, including Trillium Therapeutics Inc. (TRIL.TO) (TRIL), Concordia International (CXR), Burcon NutraScience Co. (BU.TO) (BU), Aptose Biosciences (APS), Theratechnologies (TH), and Neptune Wellness Solutions (NEPT).

BELLUS Health (TSE:BLU) and Trillium Therapeutics Inc. (TRIL.TO) (TSE:TRIL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares BELLUS Health and Trillium Therapeutics Inc. (TRIL.TO)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$17,269.0022,998.93C$-47,237,211.00C($0.60)-8.41
Trillium Therapeutics Inc. (TRIL.TO)C$115,000.0012,969.57C$-291,552,555.00C($2.90)-5.12

BELLUS Health has higher earnings, but lower revenue than Trillium Therapeutics Inc. (TRIL.TO). BELLUS Health is trading at a lower price-to-earnings ratio than Trillium Therapeutics Inc. (TRIL.TO), indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BELLUS Health and Trillium Therapeutics Inc. (TRIL.TO), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
Trillium Therapeutics Inc. (TRIL.TO)0000N/A

Trillium Therapeutics Inc. (TRIL.TO) has a consensus target price of C$25.00, indicating a potential upside of 68.80%. Given Trillium Therapeutics Inc. (TRIL.TO)'s higher possible upside, analysts plainly believe Trillium Therapeutics Inc. (TRIL.TO) is more favorable than BELLUS Health.

Profitability

This table compares BELLUS Health and Trillium Therapeutics Inc. (TRIL.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
Trillium Therapeutics Inc. (TRIL.TO)N/AN/AN/A

Summary

BELLUS Health beats Trillium Therapeutics Inc. (TRIL.TO) on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares Concordia International and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concordia InternationalN/AN/AN/A
BELLUS HealthN/AN/AN/A

Valuation and Earnings

This table compares Concordia International and BELLUS Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A
BELLUS HealthC$17,269.0022,998.93C$-47,237,211.00C($0.60)-8.41

Concordia International has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Concordia International and BELLUS Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concordia International0000N/A
BELLUS Health01202.67

Summary

Concordia International beats BELLUS Health on 4 of the 5 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Burcon NutraScience Co. (BU.TO) (TSE:BU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares BELLUS Health and Burcon NutraScience Co. (BU.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
Burcon NutraScience Co. (BU.TO)N/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for BELLUS Health and Burcon NutraScience Co. (BU.TO), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
Burcon NutraScience Co. (BU.TO)00103.00

Burcon NutraScience Co. (BU.TO) has a consensus price target of C$5.00, suggesting a potential upside of 6.61%. Given Burcon NutraScience Co. (BU.TO)'s stronger consensus rating and higher possible upside, analysts clearly believe Burcon NutraScience Co. (BU.TO) is more favorable than BELLUS Health.

Valuation & Earnings

This table compares BELLUS Health and Burcon NutraScience Co. (BU.TO)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$17,269.0022,998.93C$-47,237,211.00C($0.60)-8.41
Burcon NutraScience Co. (BU.TO)C$12,045.0041,702.26C$107,101.00C$0.004,690.00

Burcon NutraScience Co. (BU.TO) has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Burcon NutraScience Co. (BU.TO), indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience Co. (BU.TO) beats BELLUS Health on 6 of the 8 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aptose Biosciences and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
BELLUS Health01202.67

Aptose Biosciences presently has a consensus target price of C$12.00, suggesting a potential upside of 134.83%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Aptose Biosciences is more favorable than BELLUS Health.

Profitability

This table compares Aptose Biosciences and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
BELLUS HealthN/AN/AN/A

Valuation and Earnings

This table compares Aptose Biosciences and BELLUS Health's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.65)-7.87
BELLUS HealthC$17,269.0022,998.93C$-47,237,211.00C($0.60)-8.41

Aptose Biosciences has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats BELLUS Health on 3 of the 5 factors compared between the two stocks.

BELLUS Health (TSE:BLU) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for BELLUS Health and Theratechnologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
Theratechnologies02002.00

Theratechnologies has a consensus target price of C$3.75, suggesting a potential downside of 15.16%. Given Theratechnologies' higher probable upside, analysts plainly believe Theratechnologies is more favorable than BELLUS Health.

Valuation & Earnings

This table compares BELLUS Health and Theratechnologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$17,269.0022,998.93C$-47,237,211.00C($0.60)-8.41
TheratechnologiesC$63.33 million6.55C$-28,715,346.00C($0.31)-14.44

Theratechnologies has higher revenue and earnings than BELLUS Health. Theratechnologies is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BELLUS Health and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
TheratechnologiesN/AN/AN/A

Neptune Wellness Solutions (TSE:NEPT) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Neptune Wellness Solutions and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness SolutionsN/AN/AN/A
BELLUS HealthN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Neptune Wellness Solutions and BELLUS Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
BELLUS Health01202.67

Neptune Wellness Solutions presently has a consensus price target of C$4.63, indicating a potential upside of 131.25%. Given Neptune Wellness Solutions' stronger consensus rating and higher possible upside, analysts clearly believe Neptune Wellness Solutions is more favorable than BELLUS Health.

Valuation and Earnings

This table compares Neptune Wellness Solutions and BELLUS Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness SolutionsC$52.78 million6.27C$-223,415,550.00C($1.35)-1.48
BELLUS HealthC$17,269.0022,998.93C$-47,237,211.00C($0.60)-8.41

BELLUS Health has lower revenue, but higher earnings than Neptune Wellness Solutions. BELLUS Health is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.


BELLUS Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRIL
Trillium Therapeutics Inc. (TRIL.TO)
0.9$14.81+2.2%C$1.49 billionC$115,000.00-5.12
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
BU
Burcon NutraScience Co. (BU.TO)
0.8$4.69+4.7%C$502.30 millionC$12,045.004,690.00Gap Down
APS
Aptose Biosciences
1.3$5.11+0.8%C$454.09 millionN/A-7.87
Theratechnologies logo
TH
Theratechnologies
0.7$4.42+7.5%C$414.78 millionC$63.33 million-14.44Analyst Downgrade
Gap Down
NEPT
Neptune Wellness Solutions
1.2$2.00+0.5%C$330.99 millionC$52.78 million-1.48Gap Down
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5$13.60+0.2%C$315.66 millionC$39.91 million-0.22
IMV logo
IMV
IMV
1.0$4.47+4.9%C$299.91 millionC$36,000.00-7.45Gap Down
MDNA
Medicenna Therapeutics Corp. (MDNA.TO)
0.5$5.13+1.8%C$271.39 millionN/A-16.60
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
ATE
Antibe Therapeutics
1.3$5.31+8.7%C$241.64 millionC$9.33 million-6.75Gap Down
FRX
Fennec Pharmaceuticals
0.5$9.07+3.1%C$234.10 millionN/A-10.90Upcoming Earnings
High Trading Volume
RVX
Resverlogix Corp. (RVX.TO)
0.7$0.94+2.1%C$219.95 millionN/A52.22Gap Down
ONC
Oncolytics Biotech Inc. (ONC.TO)
1.2$4.23+3.3%C$183.16 millionN/A-4.69Upcoming Earnings
Gap Down
HBP
Helix BioPharma
0.5$0.88+12.5%C$124.20 millionN/A-16.30Gap Down
IPA
ImmunoPrecise Antibodies Ltd. (IPA.V)
0.4$16.71+2.6%C$123.03 millionC$16.70 million-92.83
ACST
Acasti Pharma Inc. (ACST.V)
0.7$0.94+0.0%C$88.79 millionC$81,000.0034.81Gap Down
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.61+3.3%C$66.76 millionC$11.64 million-11.96Gap Up
PDP
Pediapharm Inc. (PDP.V)
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.41+3.7%C$58.80 millionC$71,243.00-18.64High Trading Volume
PMN
ProMIS Neurosciences
0.5$0.14+7.4%C$39.11 millionC$2,767.00-5.87Gap Up
COV
Covalon Technologies Ltd. (COV.V)
0.6$1.70+3.5%C$37.44 millionC$25.80 million-6.30Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.34+3.0%C$34.02 millionC$13.02 million-0.48Gap Down
IGX
IntelGenx Technologies Corp. (IGX.V)
0.5$0.41+3.7%C$30.87 millionC$822,000.00-5.00Gap Down
QPT
Quest PharmaTech Inc. (QPT.V)
0.8$0.19+2.6%C$21.76 millionC$38,871.000.29Gap Up
CZO
Ceapro Inc. (CZO.V)
0.7$0.70+1.4%C$21.65 millionC$16.14 million21.21Gap Down
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$1.79+3.9%C$20.39 millionC$76.09 million-2.92
CTX
Crescita Therapeutics
0.6$0.88+0.0%C$18.17 millionC$16.67 million125.71Gap Down
KNE
Kane Biotech Inc. (KNE.V)
0.4$0.13+8.0%C$14.12 millionC$1.65 million-2.91Gap Up
GSD
Devonian Health Group
0.5$0.24+4.2%C$13.96 millionC$1.65 million-4.21
PAS
Pascal Biosciences
0.6$0.11+4.8%C$12.70 millionN/A-3.28Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.08+0.0%C$11.06 millionC$2.03 million-1.74
MPH
Medicure
0.7$1.60+0.0%C$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.40+10.0%C$10.16 millionC$4.12 million36.36Gap Down
HEM
Hemostemix Inc. (HEM.V)
0.6$0.42+2.4%C$9.07 millionN/A-2.50
ICO
iCo Therapeutics Inc. (ICO.V)
0.5$0.12+17.4%C$7.69 millionN/A-9.58High Trading Volume
Gap Down
IBT
IBEX Technologies
0.7$0.32+0.0%C$6.94 millionC$5.30 million7.50Gap Down
IOT
Innovotech
0.8$0.19+7.9%C$6.52 millionC$1.04 million95.00Gap Down
BCT
BriaCell Therapeutics
0.5$4.85+12.2%C$4.48 millionN/A-0.94High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5$2.95+2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.